<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00923832</url>
  </required_header>
  <id_info>
    <org_study_id>090109</org_study_id>
    <secondary_id>09-C-0109</secondary_id>
    <nct_id>NCT00923832</nct_id>
  </id_info>
  <brief_title>Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis</brief_title>
  <official_title>Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      Background:

        -  Fungal infections of the lung (pneumonia) can be caused by molds, such as Aspergillus
           and Zygomycetes, but these causes are often difficult for a doctor to diagnose. Early
           and accurate diagnosis of these infections can help doctors to select the correct
           medicines for proper treatment.

        -  A number of methods are used to diagnose fungal pneumonia. Ones that are commonly used
           in clinical practice include radiographic imaging (chest X-rays and computed tomography
           (CT) scans), blood tests, and cultures taken from fluid from the lungs (broncho-alveolar
           lavage (BAL) fluid). Other new methods may improve the diagnosis of fungal pneumonias.
           These methods include tests that can detect DNA from the fungal germ in blood and BAL
           fluid of some patients with these infections.

      Objectives:

        -  To help develop better and more accurate methods of diagnosing fungal lung infections.

        -  To detect fungal DNA and chemicals in the bloodstream and BAL fluid of immunocompromised
           patients with pneumonia.

      Eligibility:

      - Immunocompromised patients who are currently enrolled in another NIH protocol and who have
      a CT scan that shows a possible fungal infection of the lung.

      Design:

        -  Researchers will review patients' existing medical records and CT scans, and current
           pneumonia treatment plans.

        -  Patients will provide blood and BAL samples for the duration of their treatment for
           pneumonia, as required by researchers. Additional CT scans will not be performed, except
           as part of existing treatment plans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:

      Invasive fungal infections are an important cause of infectious disease, morbidity and
      mortality in immunocompromised patients with cancer, hematopoietic stem cell transplantation,
      aplastic anemia, autoimmune diseases, and primary immune deficiencies.

      Foremost among the more lethal of these infections are invasive pulmonary aspergillosis and
      zygomycosis. Early detection of these infections allows timely initiation of specific
      antifungal therapy, which may be life saving. However, early diagnosis of respiratory fungal
      infections is difficult, often leading to delay in therapy and inaccurate treatment.

      The Immunocompromised Host Section has developed a series of sensitive and highly specific
      PCR assays for the detection of these life-threatening infections. We also have characterized
      the expression of cell wall derived biomarkers, (1-3)-Beta-D-glucan and galactomannan in
      vitro and in vivo. Laboratory animal studies indicate that these assays may complement
      current diagnostic modalities and allow for more accurate and earlier detection of invasive
      pulmonary fungal infections in immunocompromised patients.

      Objectives:

      The primary objective of this study is to improve the early diagnosis of invasive pulmonary
      aspergillosis and invasive pulmonary zygomycosis in immunocompromised patients through the
      addition of molecular biomarker detection methodology to the standard diagnostic systems used
      in clinical microbiology laboratories.

      The secondary objectives are:

      A. To compare the diagnostic yield and analytical performance of the PCR, galactomannan and
      (1-3)-Beta-D-glucan to standard diagnostic systems.

      B. To evaluate the effect of different independent variables on expression of the
      aforementioned assays

      C. To characterize the variables that may contribute to therapeutic outcome (global response;
      survival)

      D. To characterize the use of these biomarkers in the context of EORTC/MSG definitions

      E. To identify genetic markers which may predispose patients to invasive fungal pulmonary
      infections.

      Eligibility:

      Immunocompromised patients currently enrolled in any NIH IRB approved Clinical Center
      protocol for the evaluation and/or treatment of his/her primary disease, or patients
      receiving treatment at the Children's National Medical Center (CNMC) who develop a pulmonary
      infiltrate radiologically compatible with invasive pulmonary aspergillosis or invasive
      pulmonary zygomycosis, by EORTC/MSG criteria.

      Design:

      This is a multi-center, prospective diagnostic interventional study.

      Patients referred to the Clinical Center for evaluation and treatment in primary research
      protocols will be eligible for enrollment in this protocol at the Clinical Center. Patients
      meeting eligibility criteria may also be enrolled from the CNMC.

      Patients who have compatible radiologic signs and are at risk for development of invasive
      pulmonary aspergillosis and invasive pulmonary zygomycosis will have specimens of
      bronchoalveolar lavage (BAL) fluid supernatant and /or tissue from lung biopsy when
      available, obtained for the measurement of diagnostic PCR for Aspergillus and Zygomycete
      identification, proteomics, cytokines and for the presence of galactomannan and
      (1-3)-Beta-D-glucan. The BAL will be performed only if clinically indicated as part of the
      patient's routine care of pneumonic infiltrates.

      Blood will be obtained from patients meeting the eligibility requirements, regardless of
      whether they have had a BAL or lung tissue biopsy, to be submitted for the measurement of
      diagnostic PCR for Aspergillus and Zygomycete identification, proteomics, cytokines, presence
      of galactomannan and (1-3)-Beta-D-glucan and host genomics.

      Digital copies of computer tomography (CT) images, that are part of routine care will
      utilized to reconstruct multi-dimensional volumetric images and correlate clinical and
      laboratory outcomes with the extent of lung volume involvement.

      Background:

      Invasive fungal infections are an important cause of infectious disease, morbidity and
      mortality in immunocompromised patients with cancer, hematopoietic stem cell transplantation,
      aplastic anemia, autoimmune diseases, and primary immune deficiencies.

      Foremost among the more lethal of these infections are invasive pulmonary aspergillosis and
      zygomycosis. Early detection of these infections allows timely initiation of specific
      antifungal therapy, which may be life saving. However, early diagnosis of respiratory fungal
      infections is difficult, often leading to delay in therapy and inaccurate treatment.

      The Immunocompromised Host Section has developed a series of sensitive and highly specific
      PCR assays for the detection of these life-threatening infections. We also have characterized
      the expression of cell wall derived biomarkers, (1-3)-Beta-D-glucan and galactomannan in
      vitro and in vivo. Laboratory animal studies indicate that these assays may complement
      current diagnostic modalities and allow for more accurate and earlier detection of invasive
      pulmonary fungal infections in immunocompromised patients.

      Objectives:

      The primary objective of this study is to improve the early diagnosis of invasive pulmonary
      aspergillosis and invasive pulmonary zygomycosis in immunocompromised patients through the
      addition of molecular biomarker detection methodology to the standard diagnostic systems used
      in clinical microbiology laboratories.

      The secondary objectives are:

      A. To compare the diagnostic yield and analytical performance of the PCR, galactomannan and
      (1-3)-Beta-D-glucan to standard diagnostic systems.

      B. To evaluate the effect of different independent variables on expression of the
      aforementioned assays

      C. To characterize the variables that may contribute to therapeutic outcome (global response;
      survival)

      D. To characterize the use of these biomarkers in the context of EORTC/MSG definitions

      E. To identify genetic markers which may predispose patients to invasive fungal pulmonary
      infections.

      Eligibility:

      Immunocompromised patients currently enrolled in any NIH IRB approved Clinical Center
      protocol for the evaluation and/or treatment of his/her primary disease, or patients
      receiving treatment at the Children's National Medical Center (CNMC) who develop a pulmonary
      infiltrate radiologically compatible with invasive pulmonary aspergillosis or invasive
      pulmonary zygomycosis, by EORTS/MSG criteria.

      Design:

      This is a multi-center, prospective diagnostic interventional study.

      Patients referred to the Clinical Center for evaluation and treatment in primary research
      protocols will be eligible for enrollment in this protocol at the Clinical Center. Patients
      meeting eligibility criteria may also be enrolled from the CNMC.

      Patients who have compatible radiologic signs and are at risk for development of invasive
      pulmonary aspergillosis and invasive pulmonary zygomycosis will have specimens of
      bronchoalveolar lavage (BAL) fluid supernatant and /or tissue from lung biopsy when
      available, obtained for the measurement of diagnostic PCR for Aspergillus and Zygomycete
      identification, proteomics, cytokines and for the presence of galactomannan and
      (1-3)-Beta-D-glucan. The BAL will be performed only if clinically indicated as part of the
      patient's routine care of pneumonic infiltrates.

      Blood will be obtained from patients meeting the eligibility requirements, regardless of
      whether they have had a BAL or lung tissue biopsy, to be submitted for the measurement of
      diagnostic PCR for Aspergillus and Zygomycete identification, proteomics, cytokines, presence
      of galactomannan and (1-3)-Beta-D-glucan and host genomics.

      Digital copies of computer tomography (CT) images, that are part of routine care will be
      utilized to reconstruct multi-dimensional volumetric images and correlate clinical and
      laboratory outcomes with the extent of lung volume involvement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 30, 2009</start_date>
  <completion_date>November 23, 2009</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <condition>Immunocompromised Host</condition>
  <condition>Invasive Pulmonary Fungal Infection</condition>
  <condition>Invasive Pulmonary Aspergillosis</condition>
  <condition>Invasive Pulmonary Zygomycosis</condition>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Patients currently enrolled in any NIH IRB approved Clinical Center protocol or under
        treatment at the CNMC who are undergoing bronchoscopy or lung biopsy for diagnosis of
        possible invasive pulmonary aspergillosis or invasive pulmonary zygomycosis.

        Informed consent of the patient or the patient's legally authorized representative.

        Fulfillment of one or more of the following EORTC/MSG host criteria:

          -  History of neutropenia (ANC &lt; 500/mm(3)) within the past 3 months temporally related
             to the onset of radiographic changes

          -  Receipt of an allogeneic HSCT

          -  Receipt of solid organ transplantation

          -  Prolonged use of corticosteroids at an average minimum dose of 0.3 mg/kg/day
             prednisone equivalent for &gt; 3 weeks

          -  Treatment with other recognized T-cell immune suppressants such as cyclosporine, TNF
             alpha blockers, specific monoclonal antibodies such as alemtuzumab, nucleoside
             analogues during the past 90 days

          -  Myelodysplastic syndrome

          -  Severe aplastic anemia

          -  Cushing's disease

          -  HIV/AIDS

          -  Primary immunodeficiencies (such as chronic granulomatous disease, severe combined
             immunodeficiency)

        The presence of one or more of the following signs on chest CT or radiograph:

          -  Dense well circumscribed lesions with or without a halo sign

          -  Air crescent sign

          -  Cavity

          -  Focal, segmental or lobar infiltrates

        EXCLUSION CRITERIA:

        Interstitial or diffuse infiltrates on chest CT or radiograph

        Inability to provide informed consent

        Children weighing less than 10 kg

        Any other concomitant condition, which in the opinion of the investigator would place the
        patient at risk by participating in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Childrens National Medical Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Becker MJ, de Marie S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol. 2000 Apr;38(4):1434-8.</citation>
    <PMID>10747121</PMID>
  </reference>
  <reference>
    <citation>Cenci E, Mencacci A, FÃ¨ d'Ostiani C, Del Sero G, Mosci P, Montagnoli C, Bacci A, Romani L. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis. 1998 Dec;178(6):1750-60.</citation>
    <PMID>9815229</PMID>
  </reference>
  <reference>
    <citation>Cortez KJ, Lyman CA, Kottilil S, Kim HS, Roilides E, Yang J, Fullmer B, Lempicki R, Walsh TJ. Functional genomics of innate host defense molecules in normal human monocytes in response to Aspergillus fumigatus. Infect Immun. 2006 Apr;74(4):2353-65.</citation>
    <PMID>16552065</PMID>
  </reference>
  <verification_date>November 23, 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2009</study_first_submitted>
  <study_first_submitted_qc>June 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2009</study_first_posted>
  <last_update_submitted>June 30, 2017</last_update_submitted>
  <last_update_submitted_qc>June 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <keyword>Fungal Infections</keyword>
  <keyword>PCR Assays</keyword>
  <keyword>Cell Wall Derived Biomarkers</keyword>
  <keyword>EORTC/MSG Definitions</keyword>
  <keyword>Molecular Assays</keyword>
  <keyword>Lung Fungal Infection</keyword>
  <keyword>Invasive Pulmonary Fungal Infection</keyword>
  <keyword>Invasive Pulmonary Aspegillosis</keyword>
  <keyword>Invasive Pulmonary Zycomycosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Invasive Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Lung Diseases, Fungal</mesh_term>
    <mesh_term>Zygomycosis</mesh_term>
    <mesh_term>Mucormycosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

